Cargando…

Assessment of New Molecular Entities Approved for Cancer Treatment in 2020

This cross-sectional study of all hematology/oncology drugs approved by the US Food and Drug Administration in 2020 assesses the functioning of the drug approval process following disruptions related to the COVID-19 pandemic.

Detalles Bibliográficos
Autores principales:	Smith, Claire E. P., Prasad, Vinay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164099/ https://www.ncbi.nlm.nih.gov/pubmed/34047795 http://dx.doi.org/10.1001/jamanetworkopen.2021.12558

Ejemplares similares

Association Between US Drug Price and Measures of Efficacy for Oncology Drugs Approved by the US Food and Drug Administration From 2015 to 2020
por: Miljković, Miloš D., et al.
Publicado: (2022)

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019
por: Chen, Emerson Y., et al.
Publicado: (2020)

Demographic Composition of Select Oncologic New Molecular Entities Approved by the FDA Between 2008 and 2017
por: Ramamoorthy, Anuradha, et al.
Publicado: (2018)

Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020
por: Olivier, Timothée, et al.
Publicado: (2023)

Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities
por: Feng, Catherine, et al.
Publicado: (2021)

Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020
por: Haslam, Alyson, et al.
Publicado: (2021)

Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action
por: Olivier, Timothée, et al.
Publicado: (2021)

Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016–2020
por: Luo, Jing, et al.
Publicado: (2023)

Characteristics of Postmarketing Studies for Vaccines Approved by the US Food and Drug Administration, 2006-2020
por: Moneer, Osman, et al.
Publicado: (2021)

Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
por: Lin, Hui-Heng, et al.
Publicado: (2017)

Bedaquiline: A new drug approved for treatment of multidrug-resistant tuberculosis
por: Deoghare, Shashank
Publicado: (2013)

Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals
por: Lammers, Austin, et al.
Publicado: (2017)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021
por: Benjamin, David J., et al.
Publicado: (2022)

The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
por: Olivier, Timothée, et al.
Publicado: (2022)

Ethics Approval
por: Ross, W M
Publicado: (1994)

Use of Clinical Outcome Assessments in New Drug Approvals by the US Food and Drug Administration Divisions of Neurology I and II
por: Schein, Yvette, et al.
Publicado: (2022)

Follicular psoriasis: an underdiagnosed entity?
por: Souza, Bruno de Castro e, et al.
Publicado: (2019)

Spinocerebellar Ataxia 42: A New Entity in Indian Subcontinent
por: Chakor, Rahul T., et al.
Publicado: (2021)

New Medical Device and Therapeutic Approvals in Otolaryngology: State of the Art Review 2020
por: Brenner, Michael J., et al.
Publicado: (2021)

Bilateral acute keratouveitis in leptospirosis: A new entity
por: Gupta, Arvind, et al.
Publicado: (2007)

Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development
por: Faucette, Stephanie, et al.
Publicado: (2017)

Nevus depigmentosus with unilateral bluish sclera, a rare entity
por: Jha, Abhijeet Kumar, et al.
Publicado: (2015)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011
por: Rathi, Vinay K., et al.
Publicado: (2020)

COVID-19 specific phobia: A new psychiatric entity?
por: Damiano, Rodolfo Furlan, et al.
Publicado: (2021)

A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020
por: Kayki-Mutlu, Gizem, et al.
Publicado: (2021)

Chronic hepatitis E: an important entity for clinicians to be aware of
por: Congly, Stephen E., et al.
Publicado: (2022)

Late‐onset Focal Dermal Elastosis—dermatoscopic and ultrasonographic assessment of this rare entity and literature review
por: Korecka, Katarzyna, et al.
Publicado: (2023)

Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond
por: Lemery, Steven, et al.
Publicado: (2022)

The need to streamline approval processes for clinical research in Canada
por: Lumia, Celeste M., et al.
Publicado: (2023)

The Solvency of Approved Societies
Publicado: (1914)

Comparing cancer drug approval systems in the United States and Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Emergence of forgotten entities
por: Sankaranantham, Murugan
Publicado: (2018)

Is RARS-T a new disease entity or a subtype of RARS or ET?
por: Bang, Soo-Mee
Publicado: (2010)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Fingolimod: The first oral drug approved by food and drug administration; A breakthrough in treatment of multiple sclerosis
por: Singh, Manish, et al.
Publicado: (2011)

Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
por: Jenei, Kristina, et al.
Publicado: (2023)

The molecular targets of approved treatments for pulmonary arterial hypertension
por: Humbert, Marc, et al.
Publicado: (2016)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g3fjriins5d5ea9nhpo4jossv3